Myriad Genetics, Inc.

500 articles with Myriad Genetics, Inc.

• Myriad Announces Research Collaboration with University of Leeds

  9/16/2019

  Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer

• Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment

  9/5/2019

  65 Percent of Patients Remained on Active Surveillance for More than Four Years

• Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention

  8/22/2019

  More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing

• Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

  8/16/2019

  Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN).

• Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

  8/7/2019

  Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.

• Kroger Health and Myriad Genetics Launch Pilot Program to Improve the Treatment of Depression

  7/10/2019

   Kroger Health, the healthcare arm of The Kroger Co. providing health, wellness, and nutrition solutions to more than 14 million people nationwide, announced its partnership with Myriad Genetics to pilot Myriad Genetics' GeneSight® pharmacogenomic test with Kroger Health Plan members.

• Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

  6/27/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer

• Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

  6/25/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer assays.

• Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

  6/19/2019

  Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad’s BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) as a companion diagnostic with the PARP inhibitor, Lynparza® (olaparib)

• Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

  6/3/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk® Hereditary Cancer test will be featured today in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO). 

• BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

  6/2/2019

   Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine,today announced that its BRACAnalysis CDx® companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with Lynparza® (olaparib) in the Phase III POLO study. 

• Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

  5/1/2019

  Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide

• EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

  4/30/2019

   Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has found that EndoPredict® test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy.

• = Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

  4/23/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from several studies at the 2019 Annual Clinical and Scientific meeting of The American College of Obstetricians and Gynecologists (ACOG) being held May 3-6, 2019 in Nashville, Tenn. 

• Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

  4/9/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® HRD CDx test. 

• Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

  4/4/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine,today announced that it has expanded its companion diagnostic collaboration with AstraZeneca and Merck (known as MSD outside the US and Canada). 

• Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

  4/2/2019

  Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present results from two important studies at the 2019 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that highlight the performance of its prenatal tests. 

• Myriad’s myPath® Melanoma Test Receives Medicare Coverage

  3/14/2019

   Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath® Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology. 

• Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib

  2/26/2019

  Myriad Will Seek FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Olaparib in this Patient Population

• Vectra® Study Published in the Journal Current Medical Research & Opinion

  2/22/2019

   Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication of an important clinical study regarding its Vectra® test in Current Medical Research & Opinion.